Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum92996Research ArticleSovremennye standarty i rekomendatsii terapii sakharnogo diabeta tipa 2: fokus na metforminSukharevaO. Yu-ShestakovaM. V-151220091112182428122021Copyright © 2009, Consilium Medicum2009[Panzgram G. Mortality and survival in type 2 (non - insulin dependent) diabetes mellitus. Diabetologia 1987; 30: 123–31.][International Diabetes Federation. New diabetes figures. Press release, 25 August 2003. www.idf.org/homr/index.cfm.][Nathan D.M., Buse J.B., Davidson M.B. et al. Medical management of hyperglycemia in type 2 diabetes: A Consensus Algorithm for the initiation and adjustment oh therapy. A consensus statement of the ADA/EASD. Diabetes Care 32: 193–203.][The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive glucose Lowering in Type 2 Diabetes. NEJM 2008; 358: 2545–59.][Marre M, Howlett H, Lehert P et al. Improved glycaemic control with metformin - glybenclamide combined therapy (Glucovance) in type 2 diabetic patients inadequately controlled on metformin. Diabetic Med 19: 673–80.][Feinglos M, Dailey G, Cefalu et al. Efect on glycemic control by addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabet Res Clin Pract 2005; 68: 167–75.][Charpentier G, Fleury F, Kabir M et al. improved glycaemic control by addition of glymepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18: 828–34.][Moses R, Slobodniuk R, Boyages S. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabet Care 22: 119–24.][Einhorn D, Rendell M, Rosenzweig J et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo - controlled study. The Pioglitazone 027 Study Group. Clin Therapeut 22: 1395–409.][Fonseca V, Rosenstock J, Patwardhan R et al. Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial. JAMA 283: 1695–702.][Rosenstock J, Brown A, Fischer J et al. Efficacy and safety of acarbose in metformin - treated patients with type 2 diabetes. Diabet Care 21: 2050–5.][Bosi et al. Effects of Vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabet Care 2007; 30: 890–5.][Charbonnel B, Karasik A, Liu J et al. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone. Diabet Care 2006; 29 (12): 2638–43.][De Fronzo R.A., Ratner R.E., Han J et al. Effects of Exenatide (Exendin - 4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes. Diabet Care 28: 1092–100.][Nathan D.M., Davidson M.B., De Fronzo R et al. Impaired fasting glucose and impaired glucose tolerance. Implications for care. Diabet Care 30: 753–9.][Knowler W, Barrett-Connor E, Fowler S.E. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.][Chiasson J.L., Josse R.G., Gomis R et al. The STOPNIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes metlitus: the STOP - NIDDM randomized trial. Lancet 2002; 359: 2072–7.][Lindstrom J, Louheranta A, Mannelin M et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3 - year results on diet and physical activity. Diabet Care 2003; 26: 3230–6.][Pan X.R., Li G.W., Hu Y.H. et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabet Care 1997; 20: 537–44.][Gerstein H.C., Yusuf S, Boxch J, Pogue J et al. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators: effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368: 1096–105.][Buchanan T.A., Xiang A.H.., Peters R.K. et al. Preservation of pancreatic _- cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high - risk Hispanic women. Diabetes 2002; 51: 2796–803.][Torgerson J.S., Hauptman J, Boldrin M.N. et al. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 151–61.][Alberti K, Zimmet P, Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet Med 2007; 24: 451–63.][American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabet Care 2009; 32 (Suppl. 1): S13–61.][Карпов О.И. Клинико - фармакологические аспекты титрования дозы метформина. Сахарный диабет. 2007; 3: 53–6.][Misbin R.I. et al. Lactic Acidosis in Patients With Diabetes Treared with Metformin. N Engl J Med 1998; 338: 265–6.][Salpeter S, Greyber E, Pasternak G et al. Risk of fatal and non - fatal lactic acidosis with metformin in type 2 diabetes. Cochrane Database Syst Rev 2003; 2: CD002967.][Salpeter S.R., Greyber E, Pasternak G.A. et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta - analysis. Arch Intern Med 2003; 163 (21): 2594–602.][Misbin R. The Phantom of Lactic Acidosis due to Metformin in Patients With Diabetes. Diabetes Care 2004; 27: 1791–3.][Bowker S.L. et al. Increased cancer - related mortality for patients with type 2 diabetes who use sulfonilureas or insulin. Diabet Care 2006; 29: 254–8.][UK Prospective Diabete Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.][Libby G, Donnelly L.A. et al. New users of metformin are at low risk of incidenr cancer. Diabet Care 2009; 32: 1620–5.][Smith U, Gale M. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1669–708.][Недосугова Л.В. Эффективность метформина в профилактике сердечно - сосудистой патологии при сахарном диабете типа 2 и метаболическом синдроме. Consilium Medicum. 2009; 11 (5): 102–9.]